News Daily News Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Caitlin E. Cox October 22, 2025
News Daily News Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data L.A. McKeown July 24, 2025
News Daily News AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review Todd Neale July 24, 2025
News Daily News Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC Michael O'Riordan June 25, 2025
News Daily News Weight-Loss Drug MariTide Gains Momentum in Phase II Trial Caitlin E. Cox June 25, 2025
News Daily News Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says Todd Neale June 06, 2025
News Daily News Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds Michael O'Riordan April 25, 2025
News Daily News Oral GLP-1 Drug Shines in Phase III ACHIEVE-1 Trial, Lilly Says Caitlin E. Cox April 17, 2025
News Daily News ACC 2025 STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients L.A. McKeown March 29, 2025
News Daily News GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm Caitlin E. Cox February 26, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025
News Daily News European Medicines Agency Investigating GLP-1 Drugs and Eye Disease L.A. McKeown January 21, 2025
News Daily News SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients L.A. McKeown October 23, 2024
News Daily News Medicaid Coverage Improves CV Risk in Some, Post Hoc Analysis Shows Todd Neale September 25, 2024
News Daily News Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes Michael O'Riordan August 19, 2024